Example Data
Below are examples of ELR submissions stored in the Washington Disease Reporting System (WDRS) replica database ELR Entire table. Data structure and formatting are real, while specific values are not.
This table is intended to give a visual of how data are structured at the end of the process from sequencing by external labs to HL7 messaging and finally storage of sequencing metadata in WA DOH’s COVID-19 surveillance system.
Values are color-coded to reflect the piece of sequencing metadata they correspond to:
Strain names. Also labelled isolate in GenBank or virus name in GISAID. These values may be full/complete or partial. As an example, the strain name for a sequence in GenBank is
WA-CDC-LAB-12345
. A lab might submit a full strain name via ELR (WA-CDC-LAB-12345
), or they might submit a partial string (12345
) which must be combined with lab-specific logic to create the final, full strain name.Pango lineages
Clinical accessions. This is the value used to link a sequencing result to a specific specimen and/or lab test. This is usually submitted as the filler order number. However, a variety of factors can influence where these data might be in ELR submissions, such as which lab is submitting the sequencing results to WA DOH and whether the same or different labs conducted the diagnostic and sequencing tests.
CASE_ID | PCO | PCO_VALUE | SPEC_COLL_DTTM | FILLER_ORD_NUM | RESULT | SPEC_PLACER_ID | FILLER_ORD_ID | SPEC_FILLER_ID | PLACER_ORD_ID |
---|---|---|---|---|---|---|---|---|---|
Helix | |||||||||
101 | Sequencing study identifier | VSX-A0199 | 2025-07-08 | VSX-A0199 | SARS-CoV-2 R.5.7 lineage | ||||
101 | 2025-07-08 | VSX-A0199 | SARS-CoV-2 R.5.7 lineage | VSX-A0199 | VSX-A0199 | ||||
101 | Age | 5 | 2025-07-08 | VSX-A0199 | SARS-CoV-2 R.5.7 lineage | ||||
102 | Sequencing study identifier | VSX-A0712 | 2025-07-04 | VSX-A0712 | SARS-CoV-2 JM.2.5 lineage | ||||
102 | 2025-07-04 | VSX-A0712 | SARS-CoV-2 JM.2.5 lineage | VSX-A0712 | VSX-A0712 | ||||
102 | Age | 15 | 2025-07-04 | VSX-A0712 | SARS-CoV-2 JM.2.5 lineage | ||||
103 | Age | 96 | 2024-05-28 | VSX-A6025 | SARS-CoV-2 X.1.12 lineage | ||||
103 | Sequencing study identifier | VSX-A6025 | 2024-05-28 | VSX-A6025 | SARS-CoV-2 X.1.12 lineage | ||||
103 | 2024-05-28 | VSX-A6025 | SARS-CoV-2 X.1.12 lineage | VSX-A6025 | VSX-A6025 | ||||
LabCorp | |||||||||
104 | Sequencing study identifier|LC Identifier | LC2679 | 2025-07-11 | 2211 | SARS-CoV-2 DQ.4.6.7 lineage; DQ.4.6.7 | 2211 | |||
105 | Sequencing study identifier | LC1227 | 2026-02-02 | 6890 | SARS-CoV-2 RAX.4.6.8 lineage; RAX.4.6.8 | 6890 | |||
106 | 2024-05-08 | 5016 | SARS-CoV-2 DE.6.5.4 lineage; DE.6.5.4 | 5016 | |||||
Quest | |||||||||
107 | 2025-10-17 | 2412 | SARS-CoV-2 O.4.3.4 lineage | OW5143V | 2412 | 2412 | OW5143V | ||
107 | Sequencing study identifierAllowable | WA-QDX-2412 | 2025-10-17 | 2412 | SARS-CoV-2 O.4.3.4 lineage | ||||
107 | Original Submitter Lab SpecimenID | OW5143V | 2025-10-17 | 2412 | SARS-CoV-2 O.4.3.4 lineage | ||||
108 | 2024-02-28 | 0178 | SARS-CoV-2 R.5.7 lineage | OW2689W | 0178 | 0178 | OW2689W | ||
108 | Sequencing study identifierAllowable | WA-QDX-0178 | 2024-02-28 | 0178 | SARS-CoV-2 R.5.7 lineage | ||||
108 | Original Submitter Lab SpecimenID | OW2689W | 2024-02-28 | 0178 | SARS-CoV-2 R.5.7 lineage | ||||
109 | Sequencing study identifierAllowable | WA-QDX-0367 | 2024-05-01 | 0367 | SARS-CoV-2 TS.2.16 lineage | ||||
109 | 2024-05-01 | 0367 | SARS-CoV-2 TS.2.16 lineage | OW2180X | 0367 | 0367 | OW2180X | ||
109 | Original Submitter Lab SpecimenID | OW2180X | 2024-05-01 | 0367 | SARS-CoV-2 TS.2.16 lineage | ||||
UW | |||||||||
110 | SEQUENCING STUDY IDENTIFIER | WA-CDC-UW8241 | 2026-03-16 | T4281 | SARS-CoV-2 CV.6.16 lineage | T4281 | T4281 | F4164 | T4281 |
111 | SEQUENCING STUDY IDENTIFIER | WA-CDC-UW0885 | 2026-03-14 | M0592 | SARS-CoV-2 M.1.5.19 lineage | M0592 | M0592 | F4164 | M0592 |
112 | SEQUENCING STUDY IDENTIFIER | WA-CDC-UW9694 | 2024-08-16 | X8663 | SARS-CoV-2 UIQ.2.12 lineage | X8663 | X8663 | F4164 | X8663 |
|
|